Biotech Values

[DewDiligence]

Based on MNTA’s CC today, I expect NVS/MNTA to launch 40mg Glatopa “at risk” (assuming they have FDA approval) when the Hatch-Waxman stay expires in Jan 2017, regardless of the status of the patent litigation with Teva. (The only exception would be if the court imposes a preliminary injunction against launching, which is highly unlikely, IMO.)